RT Journal Article
SR Electronic
T1 Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1591
OP 1597
DO 10.1136/annrheumdis-2016-210963
VO 76
IS 9
A1 Alexander Egeberg
A1 Lars Erik Kristensen
A1 Jacob P Thyssen
A1 Gunnar Hilmar Gislason
A1 Alice B Gottlieb
A1 Laura C Coates
A1 Denis Jullien
A1 Paolo Gisondi
A1 Dafna D Gladman
A1 Lone Skov
A1 Lotus Mallbris
YR 2017
UL http://ard.bmj.com/content/76/9/1591.abstract
AB Objectives To examine the incidence and temporal trends of psoriatic arthritis (PsA) in the general population in Denmark.Methods Using nationwide registry data, we estimated the number of patients with incident PsA within each 1-year period between 1997 and 2011 and calculated the rate of PsA cases within gender and age subgroups. Incidence rates were presented per 100 000 person-years.Results There was a female predominance ranging from 50.3% (1998) to 59.2% (2010), and the mean age at time of diagnosis was 47–50 years. We identified a total of 12 719 patients with PsA (prevalence=0.22%), including 9034 patients where the PsA diagnosis was made by a rheumatologist (prevalence=0.16%). Incidence rates of PsA (per 100 000 person-years) increased from 7.3 in 1997 to a peak incidence of 27.3 in 2010. Incidence rates were highest for women and patients aged 50–59 years, respectively. The use of systemic non-biologic agents, that is, methotrexate, leflunomide, ciclosporin or sulfasalazine increased over the 15-year study course and were used in 66.3% of all patients. Biologic agents (etanercept, infliximab, adalimumab, certolizumab pegol, golimumab or ustekinumab) were used in 17.7% of patients with PsA.Conclusions We found a clear trend of rising PsA incidence on a national level. While the cause remains unclear, our findings might be explained by increased attention by patients and physicians.